Combination of E-301 with PD-1– and CTLA-4–blocking antibodies augmented the inhibition of tumor growth and delayed time to progression compared with both E-301 and ICB in combination with E-301 LOF (Fig. 7, B and C). Here, CTLA4 is linked to neoplasm.